OncoMatch/Clinical Trials/NCT06883539
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
Is NCT06883539 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LXP1788 is administered intravenously via Port-A for solid tumor malignancies, cancer.
Treatment: LXP1788 is administered intravenously via Port-A — A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with advanced solid tumor. Patients with advanced solid tumors that are refractory to currently available therapies or for whom no effective treatment is available will be selected. The main questions it aims to answer are: 1. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of LXP1788 Injection 2. To evaluate the pharmacokinetics (PK) of LXP1788 Injection
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Hepatocellular Carcinoma
Renal Cell Carcinoma
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Absolute neutrophil count (ANC) < 1.5 x 10^9/L; Platelet count < 100 x 10^9/L; Hemoglobin < 9 g/dL; Having had a blood transfusion within 2 weeks of screening date is also not allowed.
Kidney function
Estimated creatinine clearance (CrCL) < 60 mL/min per the Cockcroft and Gault formula
Liver function
Total bilirubin > 1.5 x ULN; AST and ALT > 3 x ULN if no liver metastases; AST and ALT > 5 x ULN in the presence of liver metastases
Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: Bone marrow: ANC < 1.5 x 10^9/L; Platelet count < 100 x 10^9/L; Hemoglobin < 9 g/dL; Having had a blood transfusion within 2 weeks of screening date is also not allowed. Hepatic: Total bilirubin > 1.5 x ULN; AST and ALT > 3 x ULN if no liver metastases; AST and ALT > 5 x ULN in the presence of liver metastases. Renal: Estimated creatinine clearance (CrCL) < 60 mL/min per the Cockcroft and Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify